{"entity":{"id":"nct05988372","kind":"trial","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","aka":[],"tldr":"A phase 2 trial of surufatinib, serplulimab and gemcitabine in pancreatic cancer, run by Sun Yat-sen University, not yet recruiting.","summary":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) is a phase 2, randomised interventional study registered as NCT05988372 by Sun Yat-sen University, with a registry enrolment figure of 50 participants, started 2023-10-23 and due to reach its primary completion in 2023-10-23. Interventions recorded: Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine; Albumin-paclitaxel + Gemcitabine. Conditions listed: Locally Advanced Pancreatic Cancer. Primary outcome: R0 Surgical Resection Rate. Pancreatic eligibility wording from the registry: \"Pathologically confirmed unresectable locally advanced pancreatic cancer, received no surgical therapy\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05988372","url":"https://clinicaltrials.gov/study/NCT05988372"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["surufatinib","serplulimab","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05988372","phase":"2","setting":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer : a Phase II Randomized Controlled PILOT Study (SAGE)","sponsor":"Sun Yat-sen University","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05988372/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"},{"id":"surufatinib","kind":"drug","name":"Surufatinib","route":"/drugs/surufatinib/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}